Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Kimmel

Podiatrist Brookpark, OH Doctor of Podiatric Medicine

NPI 1124055918 CMS profile 186428

14401 Snow Rd, Brookpark, OH 44142

Open in the dashboard

General payments

$66,910

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Howard Kimmel of Brookpark, OH is reported in the CMS Open Payments database as having received $66,910 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $146 1
2024 General $244 3
2023 General $744 4
2022 General $28,597 60
2021 General $12,895 27
2020 General $11,268 33
2019 General $13,015 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Kimmel
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Howard Kimmel were reported at $146. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Howard Kimmel Podiatrist median Middle half National median
2019 $13,015 $196 $72–$601 $163
2020 $11,268 $118 $38–$335 $114
2021 $12,895 $169 $57–$573 $132
2022 $28,597 $220 $74–$782 $149
2023 $744 $208 $71–$635 $160
2024 $244 $237 $87–$681 $164
2025 $146 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $64,204 137 payments
  2. Treace Medical Concepts, Inc. $594 3 payments
  3. Medtronic Vascular, Inc. $322 5 payments
  4. Integra LifeSciences Corporation $304 3 payments
  5. Aroa Biosurgery Incorporated $244 3 payments
  6. Stryker Corporation $222 2 payments
  7. In2Bones USA, LLC $187 3 payments
  8. Terumo BCT, Inc. $169 2 payments
  9. Globus Medical, Inc. $151 3 payments
  10. PolyNovo North America LLC $146 1 payment
  11. Other $368 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $44,615 24 payments
  2. Travel and Lodging $12,568 54 payments
  3. Food and Beverage $5,367 87 payments
  4. Consulting Fee $4,360 4 payments
Products named General payments · program years 2019–2025
  1. VERSAJET II Other Advanced Wound Management $19,599 35 payments
  2. GRAFIX PL Other Advanced Wound Management $18,389 32 payments
  3. GRAFIX Other Advanced Wound Management $18,357 31 payments
  4. Versajet $17,718 37 payments
  5. STRAVIX $15,803 29 payments
  6. STRAVIX PL $10,851 22 payments
  7. GRAFIX XC $6,317 8 payments
  8. VERSAJET II Other Advanced Wound Management $4,684 8 payments
  9. GRAFIX PL Other Advanced Wound Management $2,699 4 payments
  10. GRAFIX Other Advanced Wound Management $2,690 3 payments
  11. Other $8,467 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

160

Median for Podiatry: 160

Drug cost

$1,343

Median for Podiatry: $2,368

Branded share of claims

26.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 19 $377
Pregabalin Generic 21 $369
Terbinafine Hcl Generic 24 $184
Cephalexin Generic 32 $125
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 23 $85
Methylprednisolone Generic 13 $83
Amitriptyline Hcl Generic 13 $62
Ciprofloxacin Hcl Generic 15 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$217,863

Medicare's payments for the services billed

Medicare patients

162

Average age 75

Services billed

874

84 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 38%
Chronic kidney disease 27%
Ischemic heart disease 26%
Heart failure 21%
Atrial fibrillation 19%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record